英科医疗(300677) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders of the listed company was CNY 54,919,704.10, a decrease of 7.95% year-on-year[8] - Operating revenue for the period was CNY 541,013,220.50, reflecting a growth of 7.88% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 53,332,531.89, down 4.67% year-on-year[8] - Basic earnings per share were CNY 0.2768, a decrease of 8.86% compared to the same period last year[8] - The weighted average return on equity was 4.01%, down 1.05% from the previous year[8] - Total operating revenue for the current period reached ¥541,013,220.50, an increase of 7.9% compared to ¥501,481,414.08 in the previous period[48] - Net profit for the current period was ¥54,920,636.84, a decrease of 7.3% from ¥59,660,335.24 in the same period last year[51] - Basic earnings per share decreased to ¥0.2768 from ¥0.3037, reflecting a decline of 8.9%[55] - The company reported a total profit for the current period of ¥62,016,857.28, down from ¥68,516,570.71 in the previous period, a decrease of 9.3%[51] - The company’s total comprehensive income for the current period was ¥56,936,160.29, compared to ¥59,848,542.69 in the previous period, reflecting a decline of 4.8%[55] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,747,009,290.51, an increase of 13.30% compared to the end of the previous year[8] - Total liabilities increased to CNY 1,304,031,839.68, up from CNY 1,151,522,123.44, representing a growth of approximately 13.3% year-over-year[34] - Current liabilities decreased to CNY 718,390,024.29 from CNY 1,072,876,400.86, a reduction of about 33%[34] - Non-current liabilities rose significantly to CNY 585,641,815.39 from CNY 78,645,722.58, marking an increase of approximately 644%[34] - Total equity attributable to shareholders rose to CNY 1,418,476,518.09 from CNY 1,273,080,261.03, an increase of approximately 11.4%[37] - The company’s total liabilities to equity ratio stands at approximately 0.91, indicating a balanced leverage position[37] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 110,653,654.75, an increase of 19.85% compared to the same period last year[8] - Cash flow from operating activities increased by 135.43% to ¥113,615,307.74 mainly from increased bank guarantee deposits and interest income[19] - The net cash flow from investing activities worsened by 144.65% to -¥339,662,353.28 due to increased cash payments for fixed and intangible asset acquisitions[19] - Cash and cash equivalents increased to CNY 373,200,485.64 from CNY 298,453,157.95, a growth of approximately 25%[38] - Cash flow from operating activities netted ¥110,653,654.75, up from ¥92,329,070.19, marking an increase of about 19.7%[79] - The net cash flow from investing activities was -323,067,824.64, worsening from -94,291,652.60 in the previous period[90] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,874[12] - The top shareholder, Liu Fangyi, held 41.55% of the shares, totaling 82,435,560 shares[12] Other Financial Metrics - The company received government subsidies amounting to CNY 3,028,052.13 during the reporting period[8] - The company reported a significant increase in undistributed profits, which reached CNY 557,560,124.89, up from CNY 461,529,979.61, a growth of about 20.8%[37] - The company’s capital reserve increased to CNY 637,306,790.25 from CNY 617,872,676.25, reflecting a growth of approximately 3.1%[37] - The company reported a financial expense of -¥5,796,338.89, significantly improved from -¥20,690,432.19 in the prior period[48] - Tax expenses rose to ¥4,467,433.85, compared to ¥3,650,704.08 in the previous period, marking an increase of 22.4%[48] - The company received tax refunds amounting to ¥99,306,025.67, compared to ¥88,761,940.01 in the previous period, reflecting an increase of approximately 11.5%[79] Research and Development - Research and development expenses increased to ¥19,219,487.57, up 4.9% from ¥18,330,334.81 in the previous period[48] - R&D expenses increased to ¥8,366,651.69 from ¥6,860,836.64, representing a growth of approximately 22%[74] - Research and development expenses increased to ¥51,731,566.43 from ¥45,870,006.67, marking a growth of 12.3%[64]